title: The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.
abstract: We investigated the efficacy of Tachyplesin III alone or combined with piperacillin-tazobactam (TZP) to prevent biofilm formation in vitro and in a rat model of Pseudomonas aeruginosa ureteral stent infection. We have observed that in vitro TZP, in presence of Tachyplesin III, showed minimal inhibitory concentrations (MIC)s twofold and minimal bactericidal concentrations (MBC)s eightfold lower. The in vivo study showed that rats that received intraperitoneal TZP showed the lowest bacterial numbers. Tachyplesin III combined with TZP showed efficacies higher than that of each single compound. Coating ureteral stents with Tachyplesin III is able to inhibit bacterial growth up to 1,000 times.
authors.affiliation: Institute of Maternal and Children's Sciences-Urology, Polytechnic University of the Marche Region, A.O. Ospedali Riuniti, 60020 Ancona, Italy. d.minardi@univpm.it
authors.forename: Daniele
authors.initials: D
authors.lastname: Minardi
authors.forename: Roberto
authors.initials: R
authors.lastname: Ghiselli
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
authors.forename: Wojciech
authors.initials: W
authors.lastname: Kamysz
authors.forename: Fiorenza
authors.initials: F
authors.lastname: Orlando
authors.forename: Carmela
authors.initials: C
authors.lastname: Silvestri
authors.forename: Gianni
authors.initials: G
authors.lastname: Parri
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Kamysz
authors.forename: Giorgio
authors.initials: G
authors.lastname: Scalise
authors.forename: Vittorio
authors.initials: V
authors.lastname: Saba
authors.forename: Muzzonigro
authors.initials: M
authors.lastname: Giovanni
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage*; D001422:Bacterial Adhesion; D018441:Biofilms / Q000187:drug effects / Q000254:growth & development; D015169:Colony Count, Microbial; D004268:DNA-Binding Proteins / Q000008:administration & dosage*; D004195:Disease Models, Animal; D054855:Drug-Eluting Stents; D066298:In Vitro Techniques; D008297:Male; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D010878:Piperacillin / Q000008:administration & dosage; D000077725:Piperacillin, Tazobactam Drug Combination; D011552:Pseudomonas Infections / Q000382:microbiology / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D014515:Ureteral Diseases / Q000382:microbiology / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D004268:DNA-Binding Proteins; D010456:Peptides, Cyclic; C057636:tachyplesin peptide, Tachypleus tridentatus; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin